Stereotactic body radiation therapy and CTLA-4 blockade as a novel therapy for advanced melanoma by unknown
POSTER PRESENTATION Open Access
Stereotactic body radiation therapy and CTLA-4
blockade as a novel therapy for advanced
melanoma
Christina Twyman1*, Andrew Rech5, Ramesh Rengan2, Robert Vonderheide4, Andy Minn3
From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013
Ipilumimab, which is a monoclonal antibody to the inhi-
bitory T-cell receptor CTLA-4, has been shown to
improve survival in patients with metastatic melanoma;
however, the response rate was only 10%, necessitating
the need to develop ways to improve treatment. Anecdo-
tal evidence suggests that stereotactic body radiation
(SBRT) might cooperate with anti-CTLA4 to improve
response rates both for irradiated and unirradiated
tumors, a concept that is being tested in a phase I/II clin-
ical trial as well as a pre-clinical mouse model. Our cen-
tral hypothesis is that SBRT delivered to an index
metastatic lesion will stimulate tumor antigen release
and improve the anti-tumor immune response to anti-
CTLA4 in advanced melanoma. To pre-clinically model
the combination of SBRT and anti-CTLA4, we are using
a syngeneic transplantation model with B16-F10 mela-
noma, which is injected to the bilateral flanks. As
expected, response of the primary tumor is generally
dictated by whether it is irradiated or not. In the unirra-
diated secondary tumor, we have observed CD8+ T-cell
dependent regression in the SBRT+anti-CTLA4 cohort
resulting in improved progression-free survival (77%)
compared to anti-CTLA4 alone (33%), SBRT alone (0%),
or the control (0%). As not all mice respond to the com-
bined therapy, we have also begun to interrogate poten-
tial mechanisms of resistance by trascriptomic profiling
of resistant tumors. To test our hypothesis clinically, we
have initiated a single-center, investigator-sponsored,
phase I/II clinical trial of escalating doses of SBRT with
ipilimumab in patients with metastatic melanoma.
Patients undergo SBRT to a single metastatic deposit fol-
lowed by standard-of-care ipilimumab. Two treatment
strata are used: bone/lung vs liver/subcutaneous. To date,
no dose-limiting toxicities have been observed in the first
12 patients enrolled on this trial. Major regressions of
irradiated as well as non-irradiated lesions have been
observed. Immune assessments to understand mechan-
ism and resistance are underway. Thus, by understanding
the genes and mechanisms associated with the SBRT
+anti-CTLA4 response, our goal is to complement an
on-going clinical trial with insight into potential biomar-
kers and therapeutic targets that may improve the selec-
tion and treatment of patients with metastatic melanoma.
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